ERBB2 and breast cancer: The current ESMO Guidelines acknowledge the higher rates of brain metastases at initial diagnosis of metastatic disease in asymptomatic patients with HER2+ breast cancer or TNBC; thus, the guideline states that subtype-oriented brain imaging may be warranted in asymptomatic patients with metastatic disease “if presence of CNS metastases will alter the choice of systemic therapy” [75].